HUFOPHA@EC2606A

Shanghai Henlius Licenses Lung Cancer Drug to Eisai for $155 Million

Fosun Pharmaceutical Subsidiary's Cyclophosphamide Injection Drug Registration Application Accepted by NMPA

F Hutchison and Eisai Sign License Agreement for Serplulimab

Fosun Pharma's Fumasilin® New Indication Drug Listing Application Accepted for Priority Review

Fosun Pharma Deputy Chairman Suggests Use of Health Insurance Data for Elderly Disease Innovation Drug R&D

Fosun Pharmaceutical to Hold Extraordinary General Meeting to Deliberate on Spin-off Listing Proposal

Fosun Pharmaceutical Completes RMB 1 Billion Innovative Technology Bond Issuance

Fosun Pharma's Subsidiary Secures Approval for Clinical Trial in Late-Stage Solid Tumor Treatment

Fosun Pharmaceutical's Subsidiary Obtains Approval for Drug Registration Application

Fosun Pharma's Subsidiary Hengenix Obtains NMPA Approval for HLX701 in Advanced Colorectal Cancer Clinical Trial

Fosun Pharma's Subsidiary Suzhou Er Ye Pharmaceuticals Receives Acceptance for Erythromycin Lactobionate for Injection Registration Application

Establishment of Zhonghui Fuhong Private Equity Investment Fund Partnership

Fosun Wanbang Resubmits Registration Application for R 潽瑞替尼 Capsules

Fosun Pharmaceutical's Subsidiary Kicks Off Phase I Clinical Trial for SRT-007 Prostate Cancer Radiopharmaceutical

Fosun Pharma Plans to Acquire Green Valley Pharmaceutical for 1.412 Billion to Integrate Innovative Drug Pipeline

Fosun Pharma Aims to Acquire 75% Equity of Green Valley Pharmaceutical for 1.412 Billion Yuan

Fosun Pharma Acquires Green Valley Pharmaceuticals Controlling Stake and Supports Clinical Trials for Gantenerumab Capsules

Fosun Pharma Discloses Sales Data and Clinical Trial Progress of 971

Fosun Pharma Aims to Acquire Green Valley for Continued Clinical Trials of 'Nine-Seven-One'

Fosun Pharmaceutical Industry Co., Ltd. signs Cooperation and Option Agreement with ClavisBio

UNI PRINTSHOP

WING CHI HLDGS

CINESE INTL

WAN KEI GROUP

CHINA WACAN

JH EDUCATION

DIGITAL DOMAIN

LOTUS HORIZON

VICO INTL HLDGS

K W NELSON GP

02196

600196

China's industrial cybersecurity firm, Tiandi Hexing, has filed for a Hong Kong IPO, reporting a 20% revenue growth but continued losses. Established in 2007, the company is backed by major investors like Zijin Mining and Fosun. The demand for industrial cybersecurity is rising due to increasing cyberattacks, with the market projected to grow significantly. Tiandi Hexing leads the fragmented market with a 6.7% share, but still faces challenges, including a loss of 94.67 million yuan in the first nine months of 2025, despite high gross profit margins.

benzinga_article

FOSUN PHARMA

China's Industrial Cybersecurity Firm Files For Hong Kong IPO - Key Investor Takeaways

510660

588130

512290

512010

Fosun Pharma Unit Gets China Acceptance for Application of Local Anaesthetic

marketscreener

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Guotai SSE STAR Brand Name Drug ETF

China Universal 800 Health Care ETF

E Fund CSI 300 Health Care ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Merchants CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Fosun Pharma Unit Gets China Acceptance for Application of Local Anaesthetic

601607

02607

Shanghai Fosun Pharmaceutical Group Co Ltd :DRUG REGISTRATION APPLICATION OF TETRACAINE HYDROCHLORIDE GEL ACCEPTED BY CHINA'S NMPA

Reuters

Shanghai Pharma

SH PHARMA

Shanghai Fosun Pharma Says Drug Registration Application Of Tetracaine Hydrochloride Gel Accepted By NMPA

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. announced that a subsidiary's drug approval application has been accepted for review by the relevant authorities. This acceptance is a step in the regulatory process, leading to further review and a GMP compliance check before potential commercial production. Currently, the acceptance of the application does not have a significant impact on the group's financial results.

Shanghai Fosun Pharmaceutical erhält Annahme für Arzneimittelzulassungsantrag

00656

FinChain, a blockchain finance platform under Fosun Wealth Holdings, has partnered with Avalanche to enhance blockchain financial innovation in Asia. They will launch FUSD, Asia's first yield-bearing RWA stable token, backed by real-world financial assets. This initiative aims to bridge traditional financial assets with the crypto-financial world, providing liquidity management tools for institutional users. The collaboration is expected to unlock significant financial channels and drive innovation in asset tokenization and DeFi applications, positioning FUSD as a foundational asset across major blockchain networks.

- FinChain has announced its integration with the Avalanche Network to advance the tokenization of real-world financial assets in Asia.  
- This partnership aims to launch FUSD, Asia's first yield-bearing RWA stable token backed by liquid financial assets, enhancing cross-chain connectivity and providing institutional users with innovative liquidity management tools.  
- The initiative is expected to unlock significant financial resources and foster compliance and interoperability across public blockchains, establishing a new landscape for trillions in traditional assets.

prnewswire

FOSUN INTL

Coinbase

Fidelity Wise Origin Bitcoin Fund - ETF

Bitwise Bitcoin ETF

WisdomTree Bitcoin Fund

Franklin Bitcoin ETF

iShares Bitcoin Trust ETF

ProShares Bitcoin Strategy ETF

Bitwise Solana Staking ETF

Invesco Galaxy Bitcoin ETF

CoinShares Bitcoin ETF

VanEck Bitcoin ETF

Siren ETF Trust Siren Nasdaq NexGen Economy ETF

ARK 21Shares Bitcoin ETF

Amplify Transform Data Sharing ETF

03:40 ETFosun Wealth Holdings' FinChain has reached a deep strategic cooperation with Avalanche.

FOSUN INTL (656.HK) had extremely low capital participation in the early trading session yesterday. Although the intraday decline was limited, it clearly maintained a trend of shrinking volume adjustments, with the stock price continuously consolidating near previous lows. Most funds have recently chosen to stay on the sidelines, and some investors attempted to speculate on short-term rebounds, but there was no effective follow-through in the market, resulting in an overall weak atmosphere. Technical signals such as MACD have been sluggish for several days, reflecting that the main forces are still observing, and the short-term bulls and bears have entered a stalemate phase. Recently, there have been no significant announcements from FOSUN INTL, and last week's rumors of "planning to sell some core assets" have continued to ferment in the community. Some funds are concerned that while the sale may improve cash flow in the short term, it could also lead to a loss of core business support. This news has increased uncertainty in the composite group sector in the short term, leading to a decrease in the willingness to allocate funds within the sector. The market is generally adopting a cautious attitude, with risk prevention becoming the main theme. Overall, the stability of the current chips has decreased, and any sudden negative news or heightened panic in the sector could lead to an inertia-driven downward trend during trading. The risk points lie in the slow progress of industry and company structural adjustments and doubts about the effectiveness of the transformation. It is recommended to closely monitor the divergence of main funds and marginal changes in news during trading, prioritize preventing uncontrollable volatility risks, maintain light positions unless necessary, and wait for clearer trends before capturing opportunities

Technical Forecast

Morning Trend | FOSUN INTL undergoes a volume reduction adjustment, what opportunities lie behind the main force's wait-and-see approach?

02696

Fosun Pharma's subsidiary, Shanghai Henlius Biotech, has licensed its lung cancer drug serplulimab to Japan's Eisai in a deal worth US$1.55 billion. Eisai will pay an upfront fee of US$75 million for exclusive commercialization rights in Japan and is eligible for additional milestone payments and royalties. This agreement reflects a trend in Chinese biotech towards long-term collaborations with global partners, as seen in other recent licensing deals. The drug has already been approved in over 40 markets, including China and the EU, and is currently undergoing trials in Japan.

南华早报

HENLIUS

Fosun Pharma unit licenses lung cancer drug to Eisai in US$1.55 billion deal

01652

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that a drug registration application from one of its subsidiaries has been accepted by the relevant regulatory authority. This announcement complies with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. No specific details about the drug or subsidiary were disclosed.

HUFOPHA@EC2606A(21717.HK)

China's Industrial Cybersecurity Firm Files For Hong Kong IPO - Key Investor Takeaways

Fosun Pharma Unit Gets China Acceptance for Application of Local Anaesthetic

Shanghai Fosun Pharma Says Drug Registration Application Of Tetracaine Hydrochloride Gel Accepted By NMPA

Shanghai Fosun Pharmaceutical erhält Annahme für Arzneimittelzulassungsantrag

03:40 ETFosun Wealth Holdings' FinChain has reached a deep strategic cooperation with Avalanche.